The postchemotherapy PSA surge syndrome

Annals of Oncology

Volumn 19, Issue 7, 2008, Pages 1308-1311

  Thuret, R ^a   Massard, C ^a   Gross Goupil, M ^a   Escudier, B ^a   Di Palma, M ^a   Bossi, A ^b   De Crevoisier, R ^b   Chauchereau, A ^a   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Department of Radiotherapy ^*  (France)

Author keywords

Castration refractory prostate cancer; Chemotherapy; Prostate specific antigen

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; GONADORELIN AGONIST; IROFULVEN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; FRANCE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; ESTRAMUSTINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; KINETICS; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; ORCHIECTOMY; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SESQUITERPENES; SYNDROME; TAXOIDS; TREATMENT OUTCOME;

EID: 46249117838     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn062     Document Type: Article

References (31)

1. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
2. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-2513.
3. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
5. Fizazi K, Le Maitre A, Hudes G et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: A meta-analysis of individual patient data. Lancet Oncol 2007; 8: 994-1000.
6. Collette L, Burzykowski T, Carroll KJ et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005; 23: 6130-6148.
7. Roessner M, de Wit R, Tannock IF et al. Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX327 study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. Proc Am Soc Clin Oncol 2005; 23: 391s (Abstr 4554).
8. Bubley, GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3471. Erratum in: J Clin Oncol 2000; 18: 2644.
9. D'Amico AV, Halabi S, Vogelzang NJ et al. A reduction in the rate of PSA rise following chemotherapy in patents with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials. Proc Am Soc Clin Oncol 2004; 24: 383s (Abstr '4506).
10. Rozhansky F, Chen MH, Cox MC et al. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 2006; 106: 63-67.
11. Scher HI, Kolvenbag GJ. The antiandrogen withdrawal syndrome in relapsed prostate cancer. Eur Urol 1997; 31 (Suppl 2): 3-7.
12. Culine S, Kattan J, Zanetta S et al. Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Am J Clin Oncol 1998; 21: 470-474.
13. Tombal B, Tourani JM, Fizazi K et al. Randomized phase II trial of irofulven (IROF) with or without prednisone in hormone-refractory prostate cancer (HRPC) patients. Proc Am Soc Clin Oncol 2003; 22: 407.
14. Hudson MA, Bahnson RR Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142: 1011-1017.
15. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-1041.
16. Killian CS, Yang N, Emrich LJ et al. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985; 45: 886-891.
17. Partin AW, Mangold LA, Lamm DM et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-848.
18. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-135.
19. Fizazi K, Slimane K, Eschwege F et al. Early undetectable serum PSA is an independent predictive factor of progression-free survival (PFS) and bone metastases in patients with localized prostate cancer treated by androgen deprivation and radiotherapy. Proc Am Soc Clin Oncol 2004; 23: 426 (Abstr 4684).
20. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439.
21. Horwich A, Peckham MJ. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Rep 1986; 70: 1329-1331.
22. de Wit R, Collette L, Sylvester R et al. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 1998; 78: 1350-1355.
23. Fizazi K, Culine S, Kramar A et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004; 22: 3868-3876.
24. Bork E, Hansen M, Urdal P et al. Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin, releasing peptide. Eur J Cancer Clin Oncol 1988; 24: 1033-1038.
25. Fischbach W, Schwarz-Wallrauch C, Jany 3. Neuron-specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer. Cancer 1989; 63: 1143-1149.
26. Fizazi K, Cojean I, Pignon JP et al. Normal serum neuron-specific enolase (NSE) value after the first cycle of chemotherapy: An early predictor of complete response and survival in small-cell lung cancer. Cancer 1998; 82: 1049-1055.
27. Fizazi K, Beuzeboc P, Di Palma M et al. A phase II trial of maintenance docetaxel and samarium in patients with castration-refractory bone metastases from prostate cancer with response or stabilization after induction docetaxel-estramustine. Prostate cancer ASCO Symposium 2006 (Abstr 222).
28. Critz FA, Williams WH, Benton JB et al, Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000; 163: 1085-1089.
29. Leibovici D, Zisman A, Lindner A et al, PSA elevation during prostate cryosurgery and subsequent decline. Urol Oncol 2005; 23: 8-11.
30. Ravery V, Meulemans A, Boccon-Gibod L. Clearance of free and total serum PSA after prostatic surgery. Eur Urol 1998; 33: 251-254.
31. Brandle E, Hautmann O, Bachem M et al. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy - a critical assessment. Urology 1999; 53: 722-730.